InnoCare's TYK2 Inhibitor Soficitinib Shows Promising Phase II Results in Atopic Dermatitis — InnoCare Pharma Limited

Event summary

InnoCare's TYK2 inhibitor soficitinib (ICP-332) demonstrated favorable safety and efficacy in a Phase II trial for moderate-to-severe atopic dermatitis, published by JAMA Dermatology on January 29, 2026.
The study showed statistically significant improvements in EASI scores with 78.2% improvement in the 80-mg group and 72.5% in the 120-mg group compared to 16.7% for placebo.
Soficitinib also exhibited rapid relief of pruritus and significant improvements in quality of life, with substantial reductions in Pruritus NRS severity and frequency scores observed as early as day 2.
Patient enrollment has been completed for the Phase III clinical trial of soficitinib in AD, with a total of 579 patients enrolled.

The big picture

InnoCare's positive Phase II results for soficitinib position it as a potential competitor in the growing market for TYK2 inhibitors, which are increasingly being targeted for various autoimmune disorders. The successful completion of patient enrollment for Phase III trials suggests strong momentum, but the company will need to navigate a competitive landscape dominated by established players like Bristol-Myers Squibb and Pfizer.

What we're watching

Clinical Development Pace: The pace at which InnoCare can advance soficitinib through Phase III trials and potential regulatory approvals will determine its competitive positioning in the dermatology market.
Market Differentiation: Whether soficitinib can differentiate itself from existing TYK2 inhibitors like deucravacitinib (BMS) and brepocitinib (Pfizer) in terms of efficacy, safety, and convenience.
Commercial Strategy: How InnoCare plans to commercialize soficitinib across multiple autoimmune indications, including atopic dermatitis, vitiligo, prurigo nodularis, CSU, and psoriasis.